Legal & General Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Legal & General Group’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-110,207	Closed	-$4.32M	–	3416
2026 Q1	$4.32M	Buy	110,207 +4,780	+5%	+$122K	﹤0.01%	1574
2025 Q4	$2.64M	Buy	105,427 +3,734	+4%	+$94.6K	﹤0.01%	1860
2025 Q3	$2.46M	Buy	101,693 +3,437	+3%	+$61.1K	﹤0.01%	1890
2025 Q2	$1.29M	Buy	98,256 +22,205	+29%	+$281K	﹤0.01%	2157
2025 Q1	$1.09M	Buy	76,051 +600	+0.8%	+$9.82K	﹤0.01%	2159
2024 Q4	$1.26M	Buy	+75,451	New	+$1.25M	﹤0.01%	2163

Legal & General Group's CNTA Position: Q2 2026 in Review

Legal & General Group sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 110,207 shares — an estimated $4.32M sold.

Legal & General Group first reported a position in CNTA in Q4 2024 and held it in 6 quarters. The position peaked at $4.32M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Legal & General Group reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Legal & General Group sold 110,207 Centessa Pharmaceuticals shares in Q2 2026, an estimated $4.32M.
Legal & General Group first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Legal & General Group's Centessa Pharmaceuticals position peaked at $4.32M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.